Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiora Pharmaceuticals

3.34
+0.05001.52%
Volume:806.00
Turnover:2.67K
Market Cap:10.02M
PE:1.97
High:3.34
Open:3.30
Low:3.30
Close:3.29
Loading ...

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Newsfile
·
13 Feb

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Newsfile
·
11 Feb

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative

Simply Wall St.
·
15 Nov 2024

Kiora Pharmaceuticals: Strategic Advancements and Financial Stability Justify Buy Rating

TIPRANKS
·
13 Nov 2024

Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Kiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial Position

TIPRANKS
·
12 Nov 2024

Kiora Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Kiora Pharmaceuticals - Expected Runway Into 2027, Excluding Any Potential Partnership Milestones

THOMSON REUTERS
·
08 Nov 2024

Kiora Pharmaceuticals Inc - Qtrly Shr Loss $0.81

THOMSON REUTERS
·
08 Nov 2024

Kiora Pharmaceuticals Inc Q3 Shr View $-0.76, REV View $7000.00 -- Lseg Ibes Data

THOMSON REUTERS
·
08 Nov 2024

Kiora Pharmaceuticals Inc expected to post a loss of 76 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Positive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy Rating

TIPRANKS
·
31 Oct 2024

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

TIPRANKS
·
29 Oct 2024

BRIEF-Kiora Pharmaceuticals Receives Ind Approval To Initiate Abacus-2, A Phase 2 Clinical Trial Of Kio-301 For Treatment Of Retinitis Pigmentosa

Reuters
·
29 Oct 2024

Kiora Pharmaceuticals: Receives Ind Approval to Initiate Abacus-2, a Phase 2 Clinical Trial of Kio-301 for Treatment of Retinitis Pigmentosa

THOMSON REUTERS
·
29 Oct 2024

Kiora Pharmaceuticals: Dosing of First Patient With Kio-301 Is Expected to Begin Next Year

THOMSON REUTERS
·
29 Oct 2024